Arctic Diagnostics Completes € 2.7M Funding

Arctic Diagnostics Ltd, a Turku, Finland-based manufacturer of a multianalyte point-of-care diagnostic system for respiratory tract infections, completed a € 2.7m funding.

The round was led by Lifeline Ventures, participation from existing investors Biothom, Veraventure and private investors.

The company intends to use the funding to expand its mariPOC® system, which diagnoses nine common viruses and bacteria that are clinically important in respiratory tract infections – such as influenza A/B, RS-virus and parainfluenza 1/2/3 viruses – in a single swab test at point-of-care.
Based on the proprietary ArcDia™ TPX detection technology (Nature Biotech 2000:18). mariPOC® was launched to the European market in late 2010.

Led by CEO Dr Aleksi Soini, Arctic plans to develop additional point-of-care tests based on its proprietary ArcDia™ TPX detection technology. Earlier this year, the company announced distribution agreement with Laboratories Leti S.L.U. in Spain, and is currently actively discussing with distributors in Europe and Asia.



Join the discussion